Amount of suitable clients: CDEC reviewed the uncertainty in the quantity of clients with moderately extreme to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people that are categorized as possessing mild or average disorder could possibly have a extreme ble